Rakovina Therapeutics to Present Abstract at the 2022 Annual Meeting of the American Association of Cancer Research (AACR)
09 mars 2022 10h56 HE
|
Rakovina Therapeutics Inc
VANCOUVER, British Columbia, March 09, 2022 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (“the Company”), a biopharmaceutical company committed to advancing new cancer therapies based...
Rakovina Therapeutics President to Join Expert Panel at the Fifth Annual DDR, ATR & PARP Inhibitors Summit
25 janv. 2022 09h00 HE
|
Rakovina Therapeutics Inc
VANCOUVER, British Columbia, Jan. 25, 2022 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSXV:RKV) (“the Company”), a biopharmaceutical company committed to advancing new cancer therapies based on...
Rakovina Therapeutics Inc. to Present at Biotech Showcase 2022
06 janv. 2022 17h01 HE
|
Rakovina Therapeutics Inc
VANCOUVER, British Columbia, Jan. 06, 2022 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSXV:RKV) (“the Company”), a biopharmaceutical company committed to advancing new cancer therapies based on...
Rakovina Therapeutics Announces Non-dilutive Financial Contributions to Support Lead Optimization of Novel Anti-cancer Agents
21 déc. 2021 09h00 HE
|
Rakovina Therapeutics Inc
VANCOUVER, British Columbia, Dec. 21, 2021 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSXV: RKV) ("the Company"), a biopharmaceutical company committed to advancing new cancer therapies based...
Rakovina Therapeutics Inc. Announces Third Quarter 2021 Financial Results and Provides Corporate Update
23 nov. 2021 17h25 HE
|
Rakovina Therapeutics Inc
VANCOUVER, British Columbia, Nov. 23, 2021 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV, the “Company”) a biopharmaceutical company committed to advancing new cancer therapies based on...
Rakovina Therapeutics Partners with St. Baldrick’s Foundation to Research and Develop New Treatments for Childhood Bone Cancer
16 nov. 2021 08h30 HE
|
Rakovina Therapeutics Inc
VANCOUVER, British Columbia, Nov. 16, 2021 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSXV: RKV) ("the Company"), a biopharmaceutical company committed to advancing new cancer therapies based...
Rakovina Therapeutics Presents at the 6th biennial Canadian Cancer Research Conference
11 nov. 2021 09h20 HE
|
Rakovina Therapeutics Inc
VANCOUVER, British Columbia, Nov. 11, 2021 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSXV: RKV) ("the Company"), a biopharmaceutical company committed to advancing new cancer therapies based...
Rakovina Therapeutics to Present at the 6th biennial Canadian Cancer Research Conference
21 oct. 2021 09h00 HE
|
Rakovina Therapeutics Inc
VANCOUVER, British Columbia, Oct. 21, 2021 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSXV: RKV) ("the Company"), a biopharmaceutical company committed to advancing new cancer therapies based...
Rakovina Therapeutics Presents at the 2021 AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics
12 oct. 2021 10h47 HE
|
Rakovina Therapeutics Inc
VANCOUVER, British Columbia, Oct. 12, 2021 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSXV: RKV) ("the Company"), a biopharmaceutical company committed to advancing new cancer therapies based...
Rakovina Therapeutics Inc. Receives Notice of Allowance for New U.S. Patent Covering kt-2000 series PARP Inhibitors
07 oct. 2021 09h00 HE
|
Rakovina Therapeutics Inc
VANCOUVER, British Columbia, Oct. 07, 2021 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (the “Company”) (TSX-V: RKV) today announced that the Company has received notice of allowance from the...